Learn how Dr. Rifkin manages bilateral cystoid macular edema as part of a systematic treatment strategy that takes into account the patient’s history, treatment preferences, and clinical response.
View Case Study
Treatment of Cystoid Macular Edema and Focal Chorioretinal Inflammation Associated With Chronic Idiopathic Uveitis
Treatment of Postoperative Cystoid Macular Edema Associated With Posterior Uveitis
IRIS IOP Brochure
Indication
XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use is a corticosteroid indicated for the treatment of macular edema associated with uveitis.
Important Safety Information
Patients should be monitored following injection for elevated intraocular pressure. See Dosage and Administration instructions in full Prescribing Information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please click here for full Prescribing Information.
References
1. XIPERE®. Prescribing Information. Clearside Biomedical Inc.
2. Chiang B, et al. Adv Drug Deliv Rev. 2018;126:58-66.
About XIPERE®
XIPERE® is a corticosteroid that treats patients with UME via an injection to the suprachoroidal space (SCS). By injecting into the SCS, drug therapy can be concentrated in appropriate target tissues, minimizing exposure to the anterior segment.2
To learn more, please visit us at xipere.com/hcp.
To learn more about Bausch + Lomb, please visit us at https://www.bausch.com.
XIPERE® and SCS® are trademarks of Clearside Biomedical, Inc. or its affiliates used under license.
© 2025 Bausch & Lomb. XIP.0121.USA.24